期刊
NATURE REVIEWS RHEUMATOLOGY
卷 14, 期 10, 页码 603-618出版社
NATURE PORTFOLIO
DOI: 10.1038/s41584-018-0081-x
关键词
-
类别
资金
- AbbVie
- Biogen
- BMS
- Celgene
- Janssen
- Lilly
- Medac
- MSD
- Nordic Pharma
- Novartis
- Pfizer
- Roche
- Sanofi-Aventis
- Swedish Orphan Biovitrum
- UCB
Adult-onset Still's disease (AoSD) is a rare but clinically well-known, polygenic, systemic autoinflammatory disease. Owing to its sporadic appearance in all adult age groups with potentially severe inflammatory onset accompanied by a broad spectrum of disease manifestation and complications, AoSD is an unsolved challenge for clinicians with limited therapeutic options. This Review provides a comprehensive insight into the complex and heterogeneous nature of AoSD, describing biomarkers of the disease and its progression and the cytokine signalling pathways that contribute to disease. The efficacy and safety of biologic therapeutic options are also discussed, and guidance for treatment decisions is provided. Improving the approach to AoSD in the future will require much closer cooperation between paediatric and adult rheumatologists to establish common diagnostic strategies, treatment targets and goals.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据